Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.90 |
| ▸ | TSHR | P16473 | 1/20 | 0.90 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.88 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.78 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354189 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7172427 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8535621 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8300827 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8943017 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8532269 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL4185457 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL5828640 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL5858775 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL2038307 | 1.00 | RARB (1.00) | RARBTP53TSHRPLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | claimed |
| EP-2057173-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | Novartis AG (CH) | 2009-05-13 | — | — | EP | claimed |
| WO-2008022771-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | claimed |
| US-6395077-B1 | INKS WITH BENZOYLBENZOIC ACID AND COLORS | XEROX CORPORATION | 2002-05-28 | — | — | US | claimed |
| EP-0579770-B1 | MACROCYCLIC LACTAM PROKINETIC AGENTS | ABBOTT LAB (US) | 1996-06-26 | — | — | EP | claimed |
| EP-0327349-B1 | Liquid crystal compounds | SHOWA SHELL SEKIYU (JP) | 1996-04-10 | — | — | EP | claimed |
| JP-2202851-A | — | — | None | — | — | JP | disclosed |
| JP-1258663-A | — | — | None | — | — | JP | disclosed |
| US-4136053-A | BIPHENYL ESTERS AND LIQUID CRYSTALLINE MIXTURES COMPRISING THEM | MERCK PATENT GESELLSCHAFT MIT BESCHANKTER HAFTUNG (DE) | 1979-01-23 | — | — | US | disclosed |
| US-4065489-A | Biphenyl esters and liquid crystalline mixtures comprising them | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | RARB 4739/4885TP53 4791/4885TSHR 2541/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | RARB 316/4885TP53 548/4885TSHR 2894/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | RARB 857/4885TP53 499/4885TSHR 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.